Positions

Overview

  • Introduction:

    Maya Khalil, M.D., is an Assistant Professor of Medicine in the Division of Hematology & Oncology at the University of Alabama at Birmingham. She received her Hematology-Oncology training at Roswell Park Comprehensive Cancer Center, where she developed expertise in clinical trial design, drug development, and patient care.

    Research:

    Her research was focused on the tumor immune microenvironment in mutation driven non-small cell lung cancer. Her focus continues to be on genomic understanding of thoracic malignancies (i.e small cell and non-small cell lung cancers), and developing novel agents that can manipulate the immune microenvironment to overcome resistance to therapies.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ├ža change.Translational lung cancer research.  9:1591-1594. 2020
    2019 Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. 2019
    2018 Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon.International Journal of Breast Cancer.  2018:8530318. 2018
    2016 Gene expression profiling of breast cancer in Lebanese women.Scientific Reports.  6:36639. 2016
    2016 Perspective of Lebanese oncologists on the symptom burden among adult cancer patients.Le Journal medical libanais. The Lebanese medical journal.  64:200-204. 2016
    2015 Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: a cross-sectional study.BMC Complementary and Alternative Medicine.  15:444. 2015
    2015 6P Screening for the Prevalence of EGFR and Alk Mutations in Lung Adenocarcinoma Patients in the Levant Area, a Prospective AnalysisAnnals of Oncology.  26:i1. 2015
    2015 Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients.BMC Cancer.  15:10. 2015

    Chapter

    Year Title Altmetric
    2020 Malignancies in immune deficiencies.  1079-1096. 2020

    Investigator On

  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by TOPALLIANCE BIOSCIENCES
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by CYTOMX THERAPEUTICS
  • Private Grant  awarded by BEIGENE
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC
  • Private Grant  awarded by NAVIRE PHARMA INC
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by BEIGENE
  • Private Grant  awarded by CYTOSITE BIOPHARMA INC
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by SEAGEN INC
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by NAVIRE PHARMA INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by MEDIVATION, INC
  • Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer Immunotherapy  awarded by NIH - OFFICE OF THE DIRECTOR
  • Education And Training

  • Doctor of Medicine, American University of Beirut 2012
  • Bachelor of Science or Mathematics in Biology, American University of Beirut 2008
  • Full Name

  • Maya Khalil